Free Trial
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Price, News & Analysis

Editas Medicine logo
$3.08 +0.22 (+7.69%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.10 +0.02 (+0.65%)
As of 05:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Editas Medicine Stock (NASDAQ:EDIT)

Key Stats

Today's Range
$2.92
$3.24
50-Day Range
$1.33
$3.08
52-Week Range
$0.91
$6.05
Volume
5.59 million shs
Average Volume
2.63 million shs
Market Capitalization
$257.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.70
Consensus Rating
Hold

Company Overview

Editas Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

EDIT MarketRank™: 

Editas Medicine scored higher than 81% of companies evaluated by MarketBeat, and ranked 166th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Editas Medicine has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 2 buy ratings, 7 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Editas Medicine has only been the subject of 3 research reports in the past 90 days.

  • Read more about Editas Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Editas Medicine are expected to grow in the coming year, from ($2.71) to ($1.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Editas Medicine is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Editas Medicine is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Editas Medicine has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Editas Medicine's valuation and earnings.
  • Percentage of Shares Shorted

    10.29% of the float of Editas Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Editas Medicine has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Editas Medicine does not currently pay a dividend.

  • Dividend Growth

    Editas Medicine does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.29% of the float of Editas Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Editas Medicine has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Editas Medicine this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,146.00 in company stock.

  • Percentage Held by Insiders

    Only 2.10% of the stock of Editas Medicine is held by insiders.

  • Percentage Held by Institutions

    71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Editas Medicine's insider trading history.
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

Editas Medicine Inc EDIT Company Vitals - U.S. News
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Editas Medicine Inc.
See More Headlines

EDIT Stock Analysis - Frequently Asked Questions

Editas Medicine's stock was trading at $1.27 at the beginning of 2025. Since then, EDIT shares have increased by 142.5% and is now trading at $3.08.

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The business had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative net margin of 701.06% and a negative trailing twelve-month return on equity of 139.24%.

Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR).

Company Calendar

Last Earnings
5/12/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EDIT
CIK
1650664
Fax
N/A
Employees
230
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$1.00
Potential Upside/Downside
+52.6%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$237.09 million
Net Margins
-701.06%
Pretax Margin
-701.06%

Debt

Sales & Book Value

Annual Sales
$32.31 million
Price / Cash Flow
N/A
Book Value
$1.63 per share
Price / Book
1.89

Miscellaneous

Free Float
81,955,000
Market Cap
$257.83 million
Optionable
Optionable
Beta
2.15

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:EDIT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners